FDA
-
-
-
-
-
-
-
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
-
-
-
-
-
-
-
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
-
-
-
-
-
-
-
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
-
-
-
-
-
-
-
EISAI PRESENTS NEW FINDINGS ON LECANEMAB'S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENC
-
-
-
-
-
-
-
Eisai to Present Research at the 2022 ASCO Gastrointestinal Cancers Symposium in Multiple Tumor Types from its Robust Oncology Portfolio
-
-
-
-
-
-
-
Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer's Disease Under The Accelerated Approval Pathway
-
-
-
-
-
-
-
Eisai Presents Breadth of Data Across Neurology Portfolio, Including Alzheimer's Disease, Insomnia and Epilepsy
-
325,452 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

